Allurion Technologies, Inc.

Allurion Technologies, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”) by the August 14, 2026 filing date applicable to a non-accelerated filer for the reasons discussed in this Form 12b-25. The Company needs additional time beyond the original filing deadline for the Form 10-Q to complete its preparation and review of items that occurred subsequent to quarter end

Allurion Technologies, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) by the November 14, 2025 filing date applicable to a non-accelerated filer for the reasons discussed in this Form 12b-25. The Company needed additional time beyond the original filing deadline for the Form 10-Q to complete its preparation and review of items that occurred subsequent to quarter end. As of the date of this notification of late filing, such preparation and review have been completed. The Company expects to file the Form 10-Q on the date hereof, which is within the five-day extension period provided by filing this notification

Allurion Technologies, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) by the August 14, 2025 filing date applicable to a non-accelerated filer for the reasons discussed in this Form 12b-25. As previously disclosed in the Company’s Form 8-K filed with the Securities and Exchange Commission on August 14, 2025, on August 14, 2025, the Audit Committee of the Board of Directors of the Company concluded that the Company’s previously issued audited consolidated financial statements as of and for the year ended December 31, 2024, as well as the prior year comparison period and each of the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, and the unaudited condensed consolidated quarterly financial statements for the quarter ended March 31, 2025 (collectively, the “Affected Financial Statements”) should no longer be relied upon and require restatement due to errors identified in the accounting related to the fair value of (i) the Company’s revenue interest financing agreement, dated as of February 9, 2023 (the “RIFA”), and (ii) the Company’s convertible senior secured notes. The Company’s management is also assessing the effect of these matters on the Company’s internal control over financial reporting and disclosure controls and procedures. As a result, the Company’s management needs more time to prepare, review and evaluate the Affected Financial Statements and Form 10-Q, including preparing the restatement of the Affected Financial Statements. The Company is working diligently to complete its financial statements and related disclosures in order to file the Form 10-Q as soon as practicable; however, there can be no assurance that the Company will be able to file the Form 10-Q within the additional time provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)